^
Association details:
| Biomarker: | EGFR mutation + LANCL2 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1997P - The Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
Published date:
09/14/2020
Excerpt:
We investigated whether the Akt kinase LANCL2 plays a role in promoting EGFR-mutant LUAD cell proliferation and drug resistance....LANCL2 overexpression rescued these effects and promoted gefitinib+pemetrexed resistance.
Secondary therapy:
pemetrexed
